Guideline-recommended treatment improves outcomes in advanced NSCLC with biomarkers
Click Here to Manage Email Alerts
Key takeaways:
- Patients with advanced NSCLC positive for biomarkers who received guideline-recommended treatment had longer OS, PFS and time to next treatment.
- Barriers to testing should be addressed to improve patient care.
CHICAGO — Patients with advanced non-small cell lung cancer who tested positive for biomarkers and subsequently received guideline-recommended treatment had better outcomes, according to research presented at ASCO Annual Meeting.
“According to [National Comprehensive Cancer Network] practice guidelines in oncology, patients with advanced non-small cell lung cancer who harbor EGFR, MET, BRAF or KRAS mutations, as well as patients without ROS1 or RET rearrangements, NTRK variants and/or high PD-L1 level, should receive an FDA approved targeted treatment,” Richard O’Hara, PhD, medical director of oncology, U.S. medical affairs at EMD Serono, said during a presentation. “As we know, adherence to these guidelines is not universal.”
O’Hara and colleagues conducted a retrospective cohort study of patients diagnosed with stage IIIB to stage IV NSCLC and were included in the TEMPUS oncology dataset. Those included in the study were diagnosed between January 2012 and December 2020, aged 18 years or older, tested positive for biomarkers and received treatment.
The researchers found that of the 2,158 patients included in the study, 55.7% were given NCCN recommended treatment.
The most common biomarkers identified in the study population were PD-L1 (38%), EGFR (32.2%) and KRAS (30.3%).
O’Hara and colleagues found that the median OS in patients given NCCN-recommended treatment at any point was 24.7 months (95% CI, 22.5–27.6), which was significantly longer than patients who were not (19.8 months; 95% CI, 17.5–22.6).
They also determined that patients who received NCCN recommended treatment had longer median PFS at 8.5 months (95% CI, 7.9–9) and longer median time to next treatment at 20.6 months (95% CI, 19.3–23.7) compared with a median PFS of 4.9 months (95% CI, 4.5–5.4) and median time to next treatment of 11 months (95% CI, 10–12.7) among patients who did not.
“As we look to the future, continued research is needed to access biomarker testing trends over time,” O’Hara said. “Reevaluation of [NSCLC] management patterns and barriers to testing in the real-world setting will be essential to improving patient care.”
Collapse
Click Here to Manage Email Alerts